BioCentury | Sep 16, 2017
Finance

Local leverage

...the candidate is the same as the only c-Met inhibitor disclosed in Lilly’s pipeline: emibetuzumab (LY2875358...
BioCentury | May 30, 2016
Clinical News

Emibetuzumab: Phase II data

...resistance to Tarceva in an open-label, international Phase II trial showed that 750 mg IV emibetuzumab...
...and emibetuzumab alone led to an ORR of 4.8%. Treatment-related adverse events were reported for emibetuzumab...
...meeting in Chicago. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Emibetuzumab ( LY2875358 , LA480...
BioCentury | Oct 19, 2015
Strategy

Sourcing biologics in China

...tyrosine kinase (c-MET; MET; HGFR ; c-Met proto-oncogene ). According to Lilly's pipeline, emibetuzumab ( LY2875358...
BioCentury | Apr 23, 2012
Clinical News

Eli Lilly preclinical data

...In animal xenograft models of c-Met-amplified NSCLC, LY2875358 alone displayed antitumor activity. Additionally, LY2875358 in combination...
...II testing to treat cancer. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY2875358 , LA480...
BioCentury | Apr 23, 2012
Clinical News

Eli Lilly preclinical data

...In animal xenograft models of gastric cancer, LY2875358 alone displayed antitumor activity. Additionally, LY2875358 in combination...
...II testing to treat cancer. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY2875358 , LA480...
Items per page:
1 - 5 of 5